Last updated: 10/14/2025 04:50:08
A study of GSK3511294 (Depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotypeNIMBLE
GSK study ID
206785
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab
Trial description: This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Annualized rate of clinically significant exacerbations over 52 weeks
Timeframe: Up to Week 52
Secondary outcomes:
Weighted mean change from Baseline in St. George's Respiratory Questionnaire (SGRQ) total score
Timeframe: Baseline (Day 1) and up to Week 52
Weighted mean change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score
Timeframe: Baseline (Day 1) and up to Week 52
Weighted mean change from Baseline in pre-bronchodilator forced expiratory volume in one second (FEV1)
Timeframe: Baseline (Day 1) and up to Week 52
Interventions:
Enrollment:
1719
Primary completion date:
2025-14-09
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Asthma
Product
Not applicable
Collaborators
IQVIA
Study date(s)
January 2021 to September 2025
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
12+ years
Accepts healthy volunteers
No
- Key inclusion criteria for study:
- Adult and adolescent participants more than or equal to (>=)12 years of age, at the time of signing the informed consent/assent.
Inclusion and exclusion criteria
Inclusion criteria:
- Key inclusion criteria for study:
- Adult and adolescent participants more than or equal to (>=)12 years of age, at the time of signing the informed consent/assent.
- Participants who have a documented physician diagnosis of asthma for >=2 years that meets the National Heart, Lung, and Blood Institute guidelines (NHLBI) or Global Initiative for Asthma (GINA) guidelines.
- Participants receiving either mepolizumab 100 milligrams (mg) or benralizumab 30 mg for >=12 months prior to screening and have a documented benefit to therapy assessed by either: (i) >=50% reduction in exacerbation frequency since initiating treatment, or (ii) >=50% reduction in maintenance OCS use since initiating treatment, or (iii) No exacerbations in the past 6 months whilst receiving anti-IL-5/5R therapy and an Asthma Control Questionnaire (ACQ)-5 score of less than or equal to (<=)1.5 at screening.
- A well-documented requirement for regular treatment with medium to high dose ICS in the 12 months prior to Visit 1 with or without maintenance OCS. The maintenance ICS dose must be >=440 micrograms (mcg) fluticasone propionate (FP) hydrofluoroalkane (HFA) product daily, or clinically comparable. Participants who are treated with medium dose ICS will also need to be treated with a LABA to qualify for inclusion.
- Current treatment with at least one additional controller medication, besides ICS [for example (e.g.), LABA, LAMA, leukotriene receptor antagonist (LTRA), or theophylline]. Key exclusion criteria for study:
- Participants with presence of a known pre-existing, clinically important lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer.
- Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis.
- A current malignancy or previous history of cancer in remission for less than 12 months prior to screening (Participants that had localized carcinoma of the skin which was resected for cure will not be excluded).
- Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
- Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis excluded prior to enrolment.
- Participants who have received Omalizumab (Xolair), dupilumab (Dupixent) or reslizumab (Cinqair/Cinqaero) within 130 days prior to Visit 1.
- Participants who have received any Monoclonal antibody (mAb) within 5 half-lives of Visit 1.
- Corrected QT interval using Fridericia’s formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block at screening Visit 1.
- Current smokers or former smokers with a smoking history of >=10 pack years (number of pack years equal to [number of cigarettes per day/20] times number of years smoked). A former smoker is defined as a participant who quit smoking at least 6 months prior to Visit 1.
- Participants with allergy/intolerance to a mAb or biologic. Key exclusion criteria for randomization:
- Evidence of a clinically significant abnormality in the 12-lead electrocardiogram (ECG) over-read conducted at Screening Visit 1, based on the evaluation of the investigator, or QTcF >=450 msec or QTcF >=480 msec for participants with Bundle Branch Block, at randomization Visit 2.
- Participants with a clinically significant asthma exacerbation in the 7 days prior to randomization should have their randomization visit delayed until the investigator considers the participant's asthma to be stable. If the 8-week screening period has elapsed, then the participant should be considered a run-in failure.
- Any changes in the dose or regimen of Baseline ICS and/or additional controller medication (except for treatment of an exacerbation) during the run-in period.
Trial location(s)
Location
GSK Investigational Site
Clearwater, FL, United States, 33765-2103
Status
Study Complete
Location
GSK Investigational Site
Hendersonville, TN, United States, 37075
Status
Study Complete
Location
GSK Investigational Site
North Palm Beach, FL, United States, 33408
Status
Study Complete
Location
GSK Investigational Site
Overland Park, KS, United States, 66210
Status
Study Complete
Location
GSK Investigational Site
Rancho Cucamonga, CA, United States, 91730
Status
Study Complete
Location
GSK Investigational Site
Williamsburg, VA, United States, 23188
Status
Study Complete
Location
GSK Investigational Site
Chesterfield, MO, United States, 63017
Status
Study Complete
Location
GSK Investigational Site
Colorado Springs, CO, United States, 80907
Status
Study Complete
Location
GSK Investigational Site
Litchfield Park, AZ, United States, 85340
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92123
Status
Study Complete
Location
GSK Investigational Site
Winston-Salem, NC, United States, 27103
Status
Study Complete
Location
GSK Investigational Site
Colorado Springs, CO, United States, 80923
Status
Study Complete
Location
GSK Investigational Site
Gulfport, Mississippi, United States, 36608
Status
Study Complete
Location
GSK Investigational Site
North Dartmouth, MA, United States, 02747
Status
Study Complete
Location
GSK Investigational Site
Orlando, Florida, United States, 32819
Status
Study Complete
Location
GSK Investigational Site
Redwood City, CA, United States, 94063
Status
Study Complete
Location
GSK Investigational Site
Huntersville, North Carolina, United States, 28078
Status
Study Complete
Location
GSK Investigational Site
Redondo Beach, CA, United States, 90277
Status
Study Complete
Location
GSK Investigational Site
NEWCASTLE UPON TYNE, United Kingdom, NE7 7DN
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, FL, United States, 32209
Status
Study Complete
Location
GSK Investigational Site
Winston-Salem, NC, United States, 27157
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, PA, United States, 19140
Status
Study Complete
Location
GSK Investigational Site
Fort Lauderdale, FL, United States, 33316
Status
Study Complete
Location
GSK Investigational Site
Huntington Beach, CA, United States, 92647
Status
Study Complete
Location
GSK Investigational Site
Newport Beach, CA, United States, 92663
Status
Study Complete
Location
GSK Investigational Site
Bristol Avon, United Kingdom, BS10 5NB
Status
Study Complete
Location
GSK Investigational Site
Columbia, SC, United States, 29204
Status
Terminated/Withdrawn
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Recruitment status
Study complete
Actual primary completion date
2025-14-09
Actual study completion date
2025-14-09
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website